Genomma Lab Internacional, S.A.B. de C.V. GNMLF
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About GNMLF
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Genomma Lab Internacional, S.A.B. de C.V. is a Mexico-based consumer products company focused on the development, marketing, and commercialization of over-the-counter (OTC) pharmaceuticals, personal care products, and beauty products. The company operates primarily in the consumer healthcare and fast-moving consumer goods sectors, with a portfolio spanning analgesics, dermatological products, cold and flu remedies, gastrointestinal treatments, oral care, shampoos, skin care, and nutritional supplements. Its business model relies heavily on brand development, direct-response advertising, retail distribution, and category positioning in mass-market channels.
The company’s principal revenue drivers are its branded OTC medicines and personal care products sold through supermarkets, pharmacies, convenience stores, wholesalers, and e-commerce platforms. Key brands include products in anti-fungal treatments, skin care, hair care, and feminine hygiene categories. Genomma Lab has built a competitive position through aggressive marketing campaigns, broad retail penetration across Latin America, and a portfolio strategy centered on recognizable regional brands. Founded in 1996 in Mexico, the company initially specialized in direct-response television advertising before evolving into a multinational consumer healthcare company listed on the Mexican Stock Exchange.
Business Operations
Genomma Lab organizes its operations around two principal business categories: OTC pharmaceuticals and Personal Care products. The company generates revenue through the sale and distribution of branded consumer products across Latin America and selected international markets. Its commercial strategy emphasizes high-volume retail distribution, category management, and advertising-driven consumer demand. The company maintains relationships with major retail chains, pharmacy networks, and distributors throughout the region.
The company operates across both domestic and international markets, with Mexico representing its largest market by revenue contribution. International operations extend across Latin America and portions of the United States market, supported by regional subsidiaries and distribution agreements. Genomma Lab controls a portfolio of proprietary brands and marketing assets while outsourcing portions of manufacturing to third-party producers alongside internal production capabilities. The company has also maintained strategic relationships with logistics providers and retailers to strengthen shelf placement and regional distribution efficiency.
Strategic Position & Investments
Genomma Lab’s strategic direction has centered on strengthening its core consumer healthcare and personal care portfolio while improving operational efficiency, profitability, and international market penetration. Growth initiatives have included expansion into higher-margin categories, digital marketing investment, supply chain optimization, and increased focus on innovation within established brands. The company has also pursued selective acquisitions and licensing agreements to expand its product portfolio and reinforce market share in targeted categories.
The company has invested in brand expansion across Latin America, particularly in countries such as Brazil, Argentina, Colombia, Chile, and the United States Hispanic consumer market. Historically, Genomma Lab has acquired and integrated regional brands and product rights to support category leadership. Strategic priorities disclosed in public filings and investor communications have included debt reduction, margin improvement, and increased operational discipline. The company has also focused on e-commerce development and consumer data analytics to strengthen direct consumer engagement and retail execution.
Geographic Footprint
Genomma Lab is headquartered in Mexico City, Mexico, and maintains a significant operational footprint throughout Latin America. Its products are distributed in multiple countries including Mexico, Brazil, Argentina, Chile, Colombia, Peru, Ecuador, and portions of the United States. Mexico remains the company’s core operating market, accounting for a substantial share of revenues and brand presence.
The company’s regional strategy emphasizes broad retail penetration and localized brand positioning across Spanish-speaking and Portuguese-speaking consumer markets. Genomma Lab’s international influence is primarily concentrated within the Americas, where it leverages regional advertising capabilities, established retail relationships, and scalable consumer health brands. Public filings and investor materials indicate continued focus on strengthening market share in key Latin American economies while selectively expanding cross-border distribution opportunities.
Leadership & Governance
Genomma Lab operates under a corporate governance structure consistent with Mexican public market requirements and oversight standards applicable to companies listed on the Bolsa Mexicana de Valores. Leadership has emphasized operational efficiency, brand-building discipline, regional expansion, and financial restructuring in recent years. The company’s governance framework includes executive leadership and a board responsible for strategic oversight, capital allocation, and compliance.
Key executives and leadership figures include:
- Rodrigo Herrera Aspra – Founder and Chairman
- Ernesto Moncada – Chief Executive Officer
- Pablo Recamier – Chief Financial Officer
- Mauricio Rosales – Chief Commercial Officer
- María Fernanda Mejía – Executive involved in corporate and operational leadership functions
Public disclosures, including SEC filings, annual reports, and investor presentations, indicate that leadership strategy has focused on strengthening profitability, reducing leverage, expanding regional brands, and increasing execution efficiency across core consumer health categories. Certain executive role disclosures may vary across reporting periods and public filings; where discrepancies exist, data is based on the most consistently reported public information available.